Comment on Nathan et al. Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial. Diabetes Care 2024;47:2155-2163 [0.03%]
关于Nathan等人的评论：平均血糖水平与HbA1c之间的关系在不同种族群体中存在差异：GRADE随机试验的子研究。糖尿病护理 2024;47:2155-2163
中文标题：关于Nathan等人对不同种族群体中平均血糖水平与HbA1c之间关系的评论：GRADE随机试验的子研究
Elizabeth Selvin
Elizabeth Selvin
Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659 [0.03%]
关于Foss-Freitas等人的评论文章：《回顾性研究中葡萄糖样肽1受体激动剂在家族性部分脂质代谢异常患者中的疗效和安全性》。糖尿病护理2024;47:653-659
Yimeng Zhou,Yongzhen Zhai
Yimeng Zhou
Comment on Casteñeda et al. The Time in Tight Range for People With Type 1 Diabetes Debate Presents a False Dichotomy [0.03%]
对Casteñeda等人的“1型糖尿病患者紧控范围的时间辩论呈现了一种错误的二分法”的评论
Gijsbert Stoet,Richard I G Holt
Gijsbert Stoet
Response to Comments on Casteñeda et al. Time in Tight Range: Appropriate When Aiming for Normal Glycemic Levels With Advanced Closed-Loop System [0.03%]
Casteñeda等人的评论回复：紧区间内的时长：在使用高级闭环系统时，瞄准正常血糖水平的适当方法
Castañeda Javier,van den Heuvel Tim,Cohen Ohad
Castañeda Javier
Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity [0.03%]
在亚洲人和白种人群中，胰高血糖素样肽1受体激动剂对心血管结局的比较疗效：针对有或无二型糖尿病以及/和超重或肥胖人群的随机试验的系统回顾及荟萃分析
Matthew M Y Lee,Nazim Ghouri,Anoop Misra et al.
Matthew M Y Lee et al.
Background: Cardiovascular outcome trials (CVOTs) suggest glucagon-like peptide 1 receptor agonists (GLP-1RAs) provide greater cardiovascular (CV) benefits in Asian compared with White individuals. ...
Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes [0.03%]
SGLT2i与DPP-4i作为联合疗法对糖尿病患者外周动脉疾病相关手术事件（截肢，支架植入或血管手术）风险的影响：一项退伍军人队列研究
Katherine E Griffin,Kathryn Snyder,Amir H Javid et al.
Katherine E Griffin et al.
Objective: To compare the risk of composite peripheral artery disease (PAD) surgical outcome, including peripheral revascularization and amputation procedures, between new users of sodium-glucose cotransporter 2 inhibitor...
Comparative Study
Diabetes care. 2025 Mar 1;48(3):361-370. DOI:10.2337/dc24-1546 2025